Unipath OTC birth control system clinical trials begin June 5 at seven U.S. sites.
This article was originally published in The Gray Sheet
UNIPATH OTC BIRTH CONTROL SYSTEM ENTERS CLINICAL TRIALS on June 5 in seven U.S. cities. The 1,200-couple study is evaluating use of the hormone analysis-based system to allow women to identify their entire fertile phase; Unipath Diagnostics already offers two home hormone-based fertility tests, the Clearblue Easy home pregnancy test and the Clearplan Easy home ovulation test.
You may also be interested in...
Celltrion has announced plans to add a third biopharmaceutical facility and a new global biotechnology research center at the Korean firm’s existing site in Songdo, Incheon, as the firm also revealed record third-quarter financial results.
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.
Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.